ATCOR’s SphygmoCor XCEL device will be used in Yale University’s clinical trial focused on maternal health.
Hypertension during pregnancy is an indicator of severe maternal morbidity
CardieX Ltd’s (ASX:CDX) subsidiary ATCOR’s SphygmoCor® XCEL device will be used by Yale University for conducting clinical trials aimed at studying the impact of aspirin in preventing preeclampsia in women with elevated blood pressure and stage 1 hypertension.
The SphygmoCor® XCEL device will be used for non-invasively measuring central blood pressure, central arterial pressure waveform, and pulse wave velocity, as well as other heart health parameters of participants.
Hypertension during pregnancy is an indicator of severe maternal morbidity affecting an estimated 6.5% of women, and this is a preventable condition.
Yale University is currently recruiting for the trial and ATCOR’s technology will provide additional data on the cardiovascular health of women enrolled in the study and support the trial’s safety.
“Significant opportunity in the maternal blood pressure market”
CardieX CEO Craig Cooper said: “We’ve been heavily focused on broadening the reach of our patented central blood pressure monitoring technology and being chosen by Yale for this unique study is a significant validation of our efforts.
“We see a significant opportunity in the maternal blood pressure market going forward with our new device.
“Our plan is to have our upcoming Pulse dual blood pressure monitor validated for home use for pregnant women, a market that has traditionally been neglected by medical device companies in the past who have focused solely on hypertension.
“Having our devices validated for pregnant women will allow us to target the upwards of 4 million pregnant women yearly in the USA and provide better solutions for women at risk of pre-eclampsia.”
Are you hiring?
Medicare rebate
This announcement shortly follows CardieX’s ATCOR also benefiting from the $40.5 million Australian federal budget allocation for ambulatory blood pressure monitoring Medicare rebates.
Cooper said: “The Medicare rebate will now give physicians a financial incentive to prescribe the Oscar 2 with SphygmoCor device in the treatment and management of blood pressure.”
